Literature DB >> 305944

Antibodies to nuclear antigens in patients with renal failure.

K D Nolph, A J Ghods, G C Sharp, A W Siemsen.   

Abstract

Nuclear material, presumably from damaged leukocytes, adheres to hemodialysis membranes. Previous studies have shown an increased prevalence of antibodies to nuclear antigens in chronic dialysis patients. Present studies verify the increased prevalence of antibodies to nuclear antigens in 52 of 243 chronic dialysis patients (21.4%). Because antibodies are present only intermittently, prevalence increases with repetitive blood sampling. In patients tested every 3 months over several years on chronic dialysis, the prevalence of antinuclear antibodies approaches 100%. The present studies also demonstrate, however, that the prevalence of antibodies is increased in patients with renal failure who have never undergone hemodialysis (10 of 86, 11.6%). Thus the tendency to form antibodies to nuclear antigens may be associated with renal failure rather than dialysis per se. Higher prevalences with increased time on dialysis and transplantation failure may accordingly reflect the greater duration of renal failure. The prevalence of antibodies to nuclear antigens was not significantly influenced by age, sex, type of kidney disease, major blood group, HLA tissue type, or coil reuse. Significantly lower hematocrits and white blood counts were noted when antibodies were present.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 305944

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  2 in total

1.  Does an association exist between PCT and SLE? Results of a study on autoantibodies in 158 patients affected with PCT.

Authors:  D Griso; A Macrì; G Biolcati; G Topi
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

Review 2.  Antigenic Targets of Patient and Maternal Autoantibodies in Autism Spectrum Disorder.

Authors:  Rut Mazón-Cabrera; Patrick Vandormael; Veerle Somers
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.